Boston Scientific (NYSE:BSX) Releases FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 3.280-3.320 for the period, compared to the consensus EPS estimate of 3.360. The company issued revenue guidance of $21.2 billion-$21.4 billion, compared to the consensus revenue estimate of $21.6 billion. Boston Scientific also updated its Q3 2026 guidance to 0.800-0.820 EPS.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $46.04 on Wednesday. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The company’s 50 day moving average is $46.78 and its 200 day moving average is $63.10. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $68.44 billion, a PE ratio of 19.27, a price-to-earnings-growth ratio of 0.87 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.36 billion. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts forecast that Boston Scientific will post 3.35 EPS for the current year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on BSX shares. UBS Group reissued a “buy” rating on shares of Boston Scientific in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Stifel Nicolaus reduced their price objective on Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Finally, Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $78.40.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock worth $554,012 in the last three months. Company insiders own 0.34% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Boston Scientific reported adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue reached $5.442 billion versus expectations of $5.36 billion. Sales increased 7.5% year over year, supported by 8.3% growth in Cardiovascular and 5.9% growth in MedSurg. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Share repurchases and strategic investment added support. The company completed its $2 billion accelerated share-repurchase program, buying approximately 40 million shares. It also invested $1.5 billion in MiRus LLC for a roughly 34% stake and an option to acquire its TAVR business, expanding Boston Scientific’s cardiovascular growth opportunities.
• Positive Sentiment: Product development remained constructive. Boston Scientific received FDA 510(k) clearance for its TruSelect 2.6 Microcatheter, while continued progress in its FARAFLEX atrial-fibrillation study could strengthen its position in pulsed-field ablation.
• Neutral Sentiment: Management launched a multiyear restructuring program. The plan is expected to cost $700 million to $800 million through 2029 and may include headcount reductions. Management expects the initiative to reduce annual costs by approximately $500 million, but the near-term expenses and job cuts introduce execution risk. Boston Scientific unveils new restructuring plan
• Negative Sentiment: Full-year and third-quarter guidance trailed analysts’ expectations. Boston Scientific forecast third-quarter adjusted EPS of $0.80–$0.82 and revenue of $5.2–$5.3 billion, below consensus estimates of $0.84 and $5.4 billion. Full-year adjusted EPS guidance of $3.28–$3.32 and revenue guidance of $21.2–$21.4 billion also fell short of consensus estimates of $3.36 and $21.6 billion.
• Negative Sentiment: Analysts have reduced valuation targets. UBS lowered its price target to $74 from $95 while maintaining a Buy rating, and Oppenheimer cut its target to $85 from $90 while retaining an Outperform rating. These reductions suggest analysts remain positive on the long-term story but see less near-term upside.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently bought and sold shares of BSX. Maverick Capital Ltd. purchased a new position in Boston Scientific during the fourth quarter worth approximately $280,735,000. Farallon Capital Management LLC grew its holdings in Boston Scientific by 56.7% in the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock valued at $709,362,000 after purchasing an additional 2,693,007 shares during the period. Marshall Wace LLP increased its position in shares of Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after buying an additional 2,301,383 shares in the last quarter. Morgan Stanley increased its position in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. Finally, Credit Agricole S A acquired a new position in shares of Boston Scientific during the 3rd quarter worth approximately $204,812,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.